Articles by Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Jim Miller

Climate Change Drives New Opportunities in Outsourcing

Ongoing changes create new opportunities for CROs and CMOs.
Jan 2, 2014

Ongoing changes create new opportunities for CROs and CMOs.

Climate Change in Outsourcing

Ongoing changes create new opportunities for CROs and CMOs.
Dec 2, 2013

Ongoing changes create new opportunities for CROs and CMOs.

The Expense of Vision in Outsourcing

Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.
Nov 6, 2013

Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.

The Expense of Vision in Outsourcing

Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.
Oct 2, 2013

Practicality of implementation should be a part of vision in the bio/pharmaceutical industry.

Outsourcing Partnerships for CMC Development

Are strategic partnerships in clinical research a model for CMC services?
Oct 1, 2013

Are strategic partnerships in clinical research a model for CMC services?

Outsourcing Partnerships for CMC Development

Are strategic partnerships in clinical research a model for CMC services?
Sep 2, 2013

Are strategic partnerships in clinical research a model for CMC services?

Stability Reigns in Contract Services

The PharmTech/PharmSource annual outsourcing survey results suggest that CDMOs may be getting complacent.
Aug 1, 2013

The PharmTech/PharmSource annual outsourcing survey results suggest that CDMOs may be getting complacent.

Drug Approval Trends Don't Extend to CMOs

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.
Jul 10, 2013

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Drug Approval Trends Don't Extend to CMOs

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.
Jun 2, 2013

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here